|
||||
TR1 NOTIFICATION OF MAJOR INTEREST IN SHARES |
||||
|
|
|||
1. Identity of the issuer or the underlying issuer |
CONVATEC GROUP PLC |
|||
2 Reason for the notification (please tick the appropriate box or boxes): |
||||
An acquisition or disposal of voting rights |
ü |
|||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached |
|
|||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments |
|
|||
An event changing the breakdown of voting rights |
|
|||
Other (please specify): |
|
|
||
3. Full name of person(s) subject to the |
NORDIC CAPITAL VI LIMITED NORDIC CAPITAL VII LIMITED
|
|||
4. Full name of shareholder(s) |
CIDRON HEALTHCARE TOPCO LIMITED CIDRON HEALTHCARE CO-INVEST LIMITED CIDRON HEALTHCARE CO-INVEST II LIMITED |
|||
5. Date of the transaction and date on |
31 MARCH 2017 |
|||
6. Date on which issuer notified: |
31 MARCH 2017 |
|||
7. Threshold(s) that is/are crossed or |
Below 17% |
|||
8. Notified details: |
||||||||||||||||
A: Voting rights attached to shares viii, ix |
||||||||||||||||
Class/type of
|
Situation previous |
Resulting situation after the triggering transaction |
||||||||||||||
Number |
Number |
Number |
Number of voting |
% of voting rights x |
||||||||||||
Direct |
Direct xi |
Indirect xii |
Direct |
Indirect |
||||||||||||
ORDINARY SHARES OF £0.10 EACH |
849,181,983 |
849,181,983 |
|
N/A |
314,158,828 |
N/A |
16.10% |
|||||||||
GB00BD3VFW73 |
||||||||||||||||
|
||||||||||||||||
B: Qualifying Financial Instruments |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Expiration |
Exercise/ |
Number of voting |
% of voting |
||||||||||||
N/A |
|
|
|
|
||||||||||||
|
||||||||||||||||
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi |
||||||||||||||||
Resulting situation after the triggering transaction |
||||||||||||||||
Type of financial |
Exercise price |
Expiration date xvii |
Exercise/ |
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|||||||||||
N/A |
|
|
|
|
Nominal |
Delta |
||||||||||
|
|
|||||||||||||||
|
||||||||||||||||
Total (A+B+C) |
||||||||||||||||
Number of voting rights |
Percentage of voting rights |
|||||||||||||||
314,158,828
|
16.10% |
|||||||||||||||
9. Chain of controlled undertakings through which the voting rights and/or the |
||
Nordic Capital VI Limited is the General Partner of Nordic Capital VI Alpha, L.P. and Nordic Capital VI Beta, L.P. (Fund VI) and is responsible for managing Fund VI.
Nordic Capital VII Limited is the General Partner of Nordic Capital VII Alpha, L.P. and Nordic Capital VII Beta, L.P. (Fund VII) and is responsible for managing Fund VII.
Fund VI and Fund VII hold shares in Cidron Healthcare Topco Limited (Topco). Topco in turn holds one management share in each of Cidron Healthcare Co-invest Limited and Cidron Healthcare Co-invest II Limited. |
||
|
||
Proxy Voting: |
||
10. Name of the proxy holder: |
N/A |
|
11. Number of voting rights proxy holder will cease |
N/A |
|
12. Date on which proxy holder will cease to hold |
N/A |
|
|
||
|
This disclosure has been calculated based on issued share capital of 1,951,472,651 shares as disclosed by ConvaTec Group Plc in its Annual Report and Accounts for the year ended 31 December 2016 |
|
14. Contact name: |
LYNDA ELLIOTT |
|
15. Contact telephone number: |
+ 44 1534 605105 |
|